These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2118421)

  • 1. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
    Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
    Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interferon-gamma in the immunotherapy of neuroblastoma.
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Herter M; Dopfer R; Müller B; Reisfeld RA; Treuner J; Niethammer D
    Prog Clin Biol Res; 1991; 366():401-7. PubMed ID: 1906184
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting effects of interferon-gamma and interleukin-4 on neopterin generation from human adherent monocytes.
    Moutabarrik A; Takahara S; Namiki M; Kameoka H; Seguchi T; Yokokawa K; Takano Y; Sonoda T; Ishibashi M; Zaid D
    Lymphokine Cytokine Res; 1992 Dec; 11(6):327-30. PubMed ID: 1477185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
    Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
    Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.
    Hahn G; Stuhlmüller B; Hain N; Kalden JR; Pfizenmaier K; Burmester GR
    J Clin Invest; 1993 Mar; 91(3):862-70. PubMed ID: 8450066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.
    Heaton KM; Ju G; Grimm EA
    Cancer Res; 1993 Jun; 53(11):2597-602. PubMed ID: 8495422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.
    Urba WJ; Kopp WC; Clark JW; Smith JW; Steis RG; Huber C; Coggin D; Longo DL
    J Clin Oncol; 1991 Oct; 9(10):1831-9. PubMed ID: 1919633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
    Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
    Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neopterin release from human endothelial cells is triggered by interferon-gamma.
    Andert SE; Griesmacher A; Zuckermann A; Müller MM
    Clin Exp Immunol; 1992 Jun; 88(3):555-8. PubMed ID: 1606740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
    Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
    Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon.
    Roberts JD; Bigelow JC; Moore AL; Belinson JL; Stewart JA; Hacker MP
    J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):53-8. PubMed ID: 8110731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.